EMA Authorised: Symtuza (darunavir;cobicistat;emtricitabine;tenofovir alafenamide) — Janssen-Cilag International NV

View source ↗

Summary

The European Medicines Agency authorised Symtuza, a fixed-dose combination antiretroviral therapy (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Janssen-Cilag International NV. Decision date: 24/07/2024